These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29869363)

  • 1. Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.
    Peyvandi F; Palla R; Franchi C; Nobili A; Rosendaal FR; Mannucci PM
    Haemophilia; 2018 Jul; 24(4):e266-e268. PubMed ID: 29869363
    [No Abstract]   [Full Text] [Related]  

  • 2. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
    Kessler CM; Iorio A
    Haemophilia; 2013 May; 19(3):351-4. PubMed ID: 23577743
    [No Abstract]   [Full Text] [Related]  

  • 3. Cluster of inhibitors among adult inpatients with haemophilia in a single institution.
    Ishaku NG; Key NS; Miller CH; Nielsen B; Buckner T; Chen SL; Hooper WC; Soucie JM
    Haemophilia; 2015 Jul; 21(4):e325-8. PubMed ID: 25939561
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII products in haemophilia A: one size fits all?
    Mannucci PM; Garagiola I
    Thromb Haemost; 2015 May; 113(5):911-4. PubMed ID: 25854290
    [No Abstract]   [Full Text] [Related]  

  • 6. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
    Ragni MV; Alabek M; Malec LM
    Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful immune tolerance in a young female with inhibitor and severe haemophilia A due to a complex genetic rearrangement.
    Zuccherato LW; Roberti MRF; Jardim LL; Rezende SM
    Haemophilia; 2018 Jul; 24(4):e283-e285. PubMed ID: 30004160
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy.
    Stemberger M; Möhnle P; Tschöp J; Ney L; Spannagl M; Reincke M
    Haemophilia; 2016 Sep; 22(5):e472-4. PubMed ID: 27480782
    [No Abstract]   [Full Text] [Related]  

  • 11. Progressing towards optimal management of haemophilia A patients with inhibitors. Foreword.
    Tarantino MD
    Haemophilia; 2013 Jan; 19 Suppl 1():1. PubMed ID: 23278992
    [No Abstract]   [Full Text] [Related]  

  • 12. A case report of a premature infant with haemophilia A and factor VIII inhibitor.
    Cartledge P; Deakin K; McKecknie L; Richards M
    Haemophilia; 2011 Jul; 17(4):711-2. PubMed ID: 21371187
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating haemophilia A with recombinant blood factors: a comparison.
    Ananyeva N; Khrenov A; Darr F; Summers R; Sarafanov A; Saenko E
    Expert Opin Pharmacother; 2004 May; 5(5):1061-70. PubMed ID: 15155108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How we choose factor VIII to treat hemophilia.
    Mannucci PM; Mancuso ME; Santagostino E
    Blood; 2012 May; 119(18):4108-14. PubMed ID: 22411872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
    Duan X; Tang M; Zhang J; Yu H; Xu R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions.
    Fischer K
    Haemophilia; 2018 Mar; 24(2):177-179. PubMed ID: 29537122
    [No Abstract]   [Full Text] [Related]  

  • 17. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 18. After the SIPPET study: Position paper of the CoMETH, the French society of haemophilia.
    Lebreton A; Castet S; Falaise C; Rugeri L; Schved JF; Wibaut B
    Haemophilia; 2018 Mar; 24(2):e55-e57. PubMed ID: 29316084
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.
    Chuansumrit A; Sirachainan N; Panuwannakorn M; Wongwerawattanakoon P; Kadegasem P; Choeyprasert W; Sasanakul W
    Haemophilia; 2013 May; 19(3):e182-3. PubMed ID: 23600908
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.